Renaissance Technologies
ARTL icon

Renaissance Technologies’s Artelo Biosciences ARTL Stock Holding History

Renaissance Technologies’s Portfolio ARTL Stock Details ARTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-75
Closed -$82K – 4203
2022
Q1 		$82K Buy
75
+30
+67% +$31K ﹤0.01% 3826
2021
Q4 		$56K Sell
45
-71
-61% -$126K ﹤0.01% 3773
2021
Q3 		$223K Sell
116
-113
-49% -$258K ﹤0.01% 3168
2021
Q2 		$663K Buy
+229
New +$704K ﹤0.01% 2847

Other funds holding ARTL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SCA
Snowden Capital Advisors New York $4.23B AUM 29.95% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return
SG
StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return

Renaissance Technologies's ARTL Position: Q2 2022 in Review

Renaissance Technologies sold out of Artelo Biosciences (ARTL) in Q2 2022, closing a stake of 75 shares — an estimated $82K sold.

Renaissance Technologies first reported a position in ARTL in Q2 2021 and held it in 4 quarters. The position peaked at $663K in Q2 2021. 12 funds tracked by Wall St. Rank hold ARTL as of Q2 2022.

  • Renaissance Technologies reported no remaining Artelo Biosciences position as of Q2 2022 after selling out during the quarter.
  • Renaissance Technologies sold 75 Artelo Biosciences shares in Q2 2022, an estimated $82K.
  • Renaissance Technologies first reported a position in Artelo Biosciences in Q2 2021 and held it in 4 quarters.
  • Renaissance Technologies's Artelo Biosciences position peaked at $663K in Q2 2021.
  • 12 funds tracked by Wall St. Rank held Artelo Biosciences as of Q2 2022.

Based on Renaissance Technologies's 13F filing for Q2 2022, filed 12 Aug 2022.